埃克替尼与厄洛替尼治疗晚期非小细胞肺癌的临床疗效及安全性研究

Comparison of clinical effects and safety between Icotinib and erlotinib in treatment of advanced non-small cell lung cancers

目的 比较埃克替尼和厄洛替尼治疗晚期非小细胞肺癌（NSCLC）的疗效和安全性,为临床治疗NSCLC提供参考.方法 将68例患者按治疗方法不同分为两组,每组34例,口服埃克替尼（125 mg,3次/d）治疗为埃克替尼组,口服厄洛替尼（150 mg,1次/d）治疗设为厄洛替尼组,两组治疗后直至病情进展或不能耐受不良反应为止,比较两组临床疗效、生存分析及不良反应.结果 埃克替尼组患者RR（总缓解率）[35.3％ （12/34）]稍高于厄洛替尼组[20.6％ （7/34）],但差异无统计学意义（P =0.177）,两组DCR（疾病控制率）及无进展生存时间（PFS）比较差异均无统计学意义（85.3％ vs 76.5％,P=0.355;8.53个月vs 6.86个月,P=0.353）.埃克替尼组不良反应总发生率低于厄洛替尼组（P =0.046）.结论 埃克替尼和厄洛替尼治疗晚期非小细胞肺癌疗效相似,埃克替尼不良反应的总发生率低于厄洛替尼,安全性更好.

Objective To compare clinical effects and safety between icotinib and erlotinib in treatment of advanced non-small cell lung cancers （NSCLC）,and provide reference for clinical treatment of NSCLC.Methods Sixty eight patients according to whether oral for icotinib were divided into two groups,each group of 34 cases,oral for icotinib （125 mg/d 3 times） treatment as for icotinib group,oral for erlotinib （150 mg,1/d） treatment as for erlotinib group.Two groups were observed until disease progression or intolerance to adverse reactions after treatment.The clinical curative effect,survival analysis,and adverse reactions were compared between two groups.Results RR （total remission rate） [35.3% （12/34）] in icotinib group was a bit higher than erlotinib group [20.6% （7/34）] without statistically significant difference （P =0.177）.DCR （disease control rates） and progression-free survival （PFS） were compared between two groups without statistical significance （85.3% vs 76.5%,P =0.355;8.53 months vs 6.86 months,P =0.353）.Icotinib group had lower incidence of adverse reactions relative to the total erlotinib group （P =0.046）.Conclusions Icotinib and erlotinib treatment of advanced non-small cell lung cancer have similar curative effect.Compared to erlotinib,icotinib has lower incidence of adverse reaction of total and better security.